Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic derm...
Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials
About this item
Full title
Author / Creator
Guttman-Yassky, Emma , Teixeira, Henrique D , Simpson, Eric L , Papp, Kim A , Pangan, Aileen L , Blauvelt, Andrew , Thaçi, Diamant , Chu, Chia-Yu , Hong, H Chih-ho , Katoh, Norito , Paller, Amy S , Calimlim, Brian , Gu, Yihua , Hu, Xiaofei , Liu, Meng , Yang, Yang , Liu, John , Tenorio, Allan R , Chu, Alvina D and Irvine, Alan D
Publisher
England: Elsevier Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: Elsevier Ltd
Subjects
More information
Scope and Contents
Contents
Upadacitinib is an oral Janus kinase (JAK) inhibitor with greater inhibitory potency for JAK1 than JAK2, JAK3, and tyrosine kinase 2. We aimed to assess the efficacy and safety of upadacitinib compared with placebo for the treatment of moderate-to-severe atopic dermatitis.
Measure Up 1 and Measure Up 2 were replicate multicentre, randomised, dou...
Alternative Titles
Full title
Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_2531542018
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2531542018
Other Identifiers
ISSN
0140-6736
E-ISSN
1474-547X
DOI
10.1016/S0140-6736(21)00588-2
